MCM
CGON icon

Manchester Capital Management’s CG Oncology CGON Stock Holding History

Manchester Capital Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.49K Hold
22
– – ﹤0.01% 1059
2025
Q4 		$914 Buy
+22
New +$910 ﹤0.01% 1149

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Manchester Capital Management's CGON Position: Q1 2026 in Review

Manchester Capital Management held its CG Oncology (CGON) position steady in Q1 2026 at 22 shares worth $1.49K. The position accounts for ﹤0.01% of the portfolio, ranked #1059.

Manchester Capital Management first reported a position in CGON in Q4 2025 and has held it in 2 quarters since. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Manchester Capital Management held 22 shares of CG Oncology worth $1.49K as of Q1 2026.
  • Manchester Capital Management left its CG Oncology share count unchanged in Q1 2026.
  • CG Oncology made up ﹤0.01% of Manchester Capital Management's portfolio in Q1 2026, its #1059 holding.
  • Manchester Capital Management first reported a position in CG Oncology in Q4 2025 and has held it in 2 quarters since.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.